The regulatory journey to accelerated approval for Biogen, Inc. and Eisai Co., Ltd.’s Alzheimer’s drug Aduhelm (aducanumab-avwa) was circuitous – a destination briefly visited but one that reappeared on the horizon only as time ticked down on the application’s 7 June user fee goal date.
US Food and Drug Administration review documents show that as early as December 2014, there was discussion with Biogen about...






